{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:22:36Z","timestamp":1779308556111,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Invasive fungal diseases (IFDs) are a significant cause of morbidity and mortality in pediatric patients with hematologic malignancies including acute leukemia. Our study aimed to compare the efficacy of liposomal amphotericin B (L-AMB), posaconazole or micafungin as primary antifungal prophylaxis (PAP) in pediatric patients with acute leukemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study enrolled 95 pediatric patients with acute lymphoblastic leukemia (n\u2009=\u200970) or acute myeloid leukemia (n\u2009=\u200925), undergoing chemotherapy, including those undergoing allogeneic hematopoietic stem cell transplantation at the Department of Pediatrics, Jena University Hospital, Jena, Germany. PAP regimens included L-AMB (1\u00a0mg\/kg\/day or 3\u00a0mg\/kg twice weekly, intravenously), posaconazole (100\u2013300\u00a0mg\/day, according to blood concentration, orally or intravenously) and micafungin (1\u00a0mg\/kg\/day or 3\u00a0mg\/kg twice weekly, intravenously). Thirty-four patients (35.8%) received L-AMB, 37 patients (38.9%) received posaconazole, and 24 patients (25.3%) received micafungin. Patients with a history of IFD or concurrent or changing PAP were excluded. The primary endpoint was the occurrence of breakthrough IFD, while secondary endpoint included IFD-free survival. Statistical analyses were performed using Kaplan\u2013Meier survival analysis, Gray\u2019s test and Cox regression to evaluate IFD-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall incidence of IFD was 14.7% (14 of 95 patients). IFD developed in 10 of 33 patients (29.4%) receiving L-AMB, in 4 of 38 (10.8%) patients receiving posaconazole and in none of the patients receiving micafungin. IFD-free survival was 70.6% in the L-AMB group, 89.2% in the posaconazole group and 100% in the micafungin group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005, log-rank test). Significant differences were also observed in the cumulative incidences of breakthrough IFDs (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006) assessed by Gray\u2019s test. In multivariate Cox analysis, dichotomized prophylaxis regimes (posaconazole or micafungin\u00a0vs.\u202fL-AMB) were independently associated with a reduced risk of IFD (HR\u2009=\u20090.244; 95% CI 0.076\u20130.777;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017). Age\u2009\u2265\u200910\u00a0years\u00a0predicted inferior IFD-free survival (HR\u2009=\u20093.665; 95% CI 1.224\u201310.980;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.020).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We found a significant difference in efficacy between the three antifungal prophylaxis regimens. In our study, micafungin achieved the lowest IFD breakthrough rate. However, multicenter clinical studies would be needed to confirm the results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-025-06289-5","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T13:21:03Z","timestamp":1755955263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative study of liposomal amphotericin B, posaconazole, and micafungin for primary antifungal prophylaxis in pediatric patients with acute leukemia"],"prefix":"10.1007","volume":"151","author":[{"given":"Anna Sophia","family":"Gottschlich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Milde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Gruhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"6289_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.00705-08","volume":"53","author":"D Andes","year":"2009","unstructured":"Andes D, Pascual A, Marchetti O (2009) Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 53:24\u201334. https:\/\/doi.org\/10.1128\/AAC.00705-08","journal-title":"Antimicrob Agents Chemother"},{"key":"6289_CR2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40262-021-00994-3","volume":"60","author":"D Bury","year":"2021","unstructured":"Bury D, Tissing WJE, Muilwijk EW, Wolfs TFW, Bruggemann RJ (2021) Clinical pharmacokinetics of triazoles in pediatric patients. Clin Pharmacokinet 60:1103\u20131147. https:\/\/doi.org\/10.1007\/s40262-021-00994-3","journal-title":"Clin Pharmacokinet"},{"key":"6289_CR3","doi-asserted-by":"publisher","first-page":"107058","DOI":"10.1016\/j.ijantimicag.2023.107058","volume":"63","author":"D Bury","year":"2024","unstructured":"Bury D, Wolfs TFW, Muilwijk EW, Fiocco M, Pieters R, Bruggemann RJ, Tissing WJE (2024) Micafungin twice-a-week for prophylaxis of invasive Aspergillus infections in children with acute lymphoblastic leukaemia: a controlled cohort study. Int J Antimicrob Agents 63:107058. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107058","journal-title":"Int J Antimicrob Agents"},{"key":"6289_CR4","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1093\/jac\/dkx133","volume":"72","author":"OA Cornely","year":"2017","unstructured":"Cornely OA, Leguay T, Maertens J, Vehreschild M, Anagnostopoulos A, Castagnola C, Verga L, Rieger C, Kondakci M, Harter G, Duarte RF, Allione B, Cordonnier C, Heussel CP, Morrissey CO, Agrawal SG, Donnelly JP, Bresnik M, Hawkins MJ, Garner W, Gokbuget N, AmBiGuard Study G (2017) Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother 72:2359\u20132367. https:\/\/doi.org\/10.1093\/jac\/dkx133","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"6289_CR5","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, Kontoyiannis DP, Kullberg BJ, Lagrou K, Lamoth F, Lehrnbecher T, Loeffler J, Lortholary O, Maertens J, Marchetti O, Marr KA, Masur H, Meis JF, Morrisey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, Roilides E, Ruhnke M, Prokop CS, Shoham S, Slavin MA, Stevens DA, Thompson GR, Vazquez JA, Viscoli C, Walsh TJ, Warris A, Wheat LJ, White PL, Zaoutis TE, Pappas PG (2020) Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 71(6):1367\u20131376. https:\/\/doi.org\/10.1093\/cid\/ciz1008","journal-title":"Clin Infect Dis"},{"key":"6289_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/microorganisms12010145","volume":"12","author":"TR Gal Etzioni","year":"2024","unstructured":"Gal Etzioni TR, Fainshtain N, Nitzan-Luques A, Goldstein G, Weinreb S, Temper V, Korem M, Averbuch D (2024) Invasive fungal infections in children with acute leukemia: epidemiology, risk factors, and outcome. Microorganisms 12:145. https:\/\/doi.org\/10.3390\/microorganisms12010145","journal-title":"Microorganisms"},{"key":"6289_CR7","doi-asserted-by":"publisher","DOI":"10.4081\/pr.2011.e6","volume":"3","author":"M Giacchino","year":"2011","unstructured":"Giacchino M, Milano GM, Carraro F, Bezzio S, Pegoraro A, Aversa F, Cesaro S (2011) Current evidence of antifungal prophylaxis and therapy in pediatric patients. Pediatr Rep 3:e6. https:\/\/doi.org\/10.4081\/pr.2011.e6","journal-title":"Pediatr Rep"},{"key":"6289_CR8","doi-asserted-by":"publisher","first-page":"106084","DOI":"10.1016\/j.ijantimicag.2020.106084","volume":"56","author":"AH Groll","year":"2020","unstructured":"Groll AH, Abdel-Azim H, Lehrnbecher T, Steinbach WJ, Paschke A, Mangin E, Winchell GA, Waskin H, Bruno CJ (2020) Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial. Int J Antimicrob Agents 56:106084. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106084","journal-title":"Int J Antimicrob Agents"},{"key":"6289_CR9","doi-asserted-by":"publisher","first-page":"e13654","DOI":"10.1111\/myc.13654","volume":"67","author":"AH Groll","year":"2024","unstructured":"Groll AH, Korholz K, Holterhus M, Lehrnbecher T (2024) New and emerging options for management of invasive fungal diseases in paediatric patients. Mycoses 67:e13654. https:\/\/doi.org\/10.1111\/myc.13654","journal-title":"Mycoses"},{"key":"6289_CR10","doi-asserted-by":"publisher","unstructured":"Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, Roilides E, Styczynski J, Warris A, Lehrnbecher T, Fourth European Conference on Infections in L, Infectious Diseases Working Party of the European Group for Blood Marrow T, Infectious Diseases Group of the European Organisation for R, Treatment of C, International Immunocompromised Host S, European Leukaemia N (2014) Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 15:e327\u2013e340. https:\/\/doi.org\/10.1016\/S1470-2045(14)70017-8","DOI":"10.1016\/S1470-2045(14)70017-8"},{"key":"6289_CR11","doi-asserted-by":"publisher","unstructured":"Groll AH, Pana D, Lanternier F, Mesini A, Ammann RA, Averbuch D, Castagnola E, Cesaro S, Engelhard D, Garcia-Vidal C, Kanerva J, Ritz N, Roilides E, Styczynski J, Warris A, Lehrnbecher T, (2021) 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol 22:e254\u2013e269. https:\/\/doi.org\/10.1016\/S1470-2045(20)30723-3","DOI":"10.1016\/S1470-2045(20)30723-3"},{"key":"6289_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/clpt.2010.64","volume":"88","author":"SH Jang","year":"2010","unstructured":"Jang SH, Colangelo PM, Gobburu JV (2010) Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 88:115\u2013119. https:\/\/doi.org\/10.1038\/clpt.2010.64","journal-title":"Clin Pharmacol Ther"},{"key":"6289_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00355-18","volume":"62","author":"CH Lee","year":"2018","unstructured":"Lee CH, Lin C, Ho CL, Lin JC (2018) Primary fungal prophylaxis in hematological malignancy: a network meta-analysis of randomized controlled trials. Antimicrob Agents Chemother 62:10\u20131128. https:\/\/doi.org\/10.1128\/AAC.00355-18","journal-title":"Antimicrob Agents Chemother"},{"key":"6289_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3389\/fmicb.2019.00681","volume":"10","author":"T Lehrnbecher","year":"2019","unstructured":"Lehrnbecher T, Schoning S, Poyer F, Georg J, Becker A, Gordon K, Attarbaschi A, Groll AH (2019) Incidence and outcome of invasive fungal diseases in children with hematological malignancies and\/or allogeneic hematopoietic stem cell transplantation: results of a prospective multicenter study. Front Microbiol 10:681. https:\/\/doi.org\/10.3389\/fmicb.2019.00681","journal-title":"Front Microbiol"},{"key":"6289_CR15","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.20.00158","volume":"38","author":"T Lehrnbecher","year":"2020","unstructured":"Lehrnbecher T, Fisher BT, Phillips B, Beauchemin M, Carlesse F, Castagnola E, Duong N, Dupuis LL, Fioravantti V, Groll AH, Haeusler GM, Roilides E, Science M, Steinbach WJ, Tissing W, Warris A, Patel P, Robinson PD, Sung L (2020) Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol 38:3205\u20133216. https:\/\/doi.org\/10.1200\/JCO.20.00158","journal-title":"J Clin Oncol"},{"key":"6289_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/jof11010038","volume":"11","author":"K Liszka","year":"2025","unstructured":"Liszka K, Marschollek P, Przystupski D, Fraczkiewicz J, Mielcarek-Siedziuk M, Olejnik I, Gamrot Z, Haze N, Kwella A, Zalewska P, Resztak M, Ussowicz M, Kalwak K (2025) Efficacy and safety assessment of antifungal prophylaxis with posaconazole using therapeutic drug monitoring in pediatric patients with oncohematological disorders-a single-centre study. J Fungi (Basel) 11:38. https:\/\/doi.org\/10.3390\/jof11010038","journal-title":"J Fungi (Basel)"},{"key":"6289_CR17","doi-asserted-by":"publisher","unstructured":"Lopez-Sanchez C, Valcarcel D, Gomez V, Lopez-Jimenez J, Serrano D, Rubio V, Solano C, Vazquez L, Ruiz I, Grupo Espanol de Trasplante H (2020) Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC). Rev Esp Quimioter 33:110\u2013115. https:\/\/doi.org\/10.37201\/req\/094.2019","DOI":"10.37201\/req\/094.2019"},{"key":"6289_CR18","doi-asserted-by":"publisher","first-page":"ii11","DOI":"10.1093\/jac\/dkac352","volume":"77","author":"J Maertens","year":"2022","unstructured":"Maertens J, Pagano L, Azoulay E, Warris A (2022) Liposomal amphotericin B-the present. J Antimicrob Chemother 77:ii11\u2013ii20. https:\/\/doi.org\/10.1093\/jac\/dkac352","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"6289_CR19","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2165\/00003495-200767110-00004","volume":"67","author":"G Maschmeyer","year":"2007","unstructured":"Maschmeyer G, Haas A, Cornely OA (2007) Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 67(11):1567\u20131601. https:\/\/doi.org\/10.2165\/00003495-200767110-00004","journal-title":"Drugs"},{"key":"6289_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","volume":"97","author":"SC Mellinghoff","year":"2018","unstructured":"Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, Hasenkamp J, Kiehl M, Koldehoff M, Krause SW, Lehners N, von Lilienfeld-Toal M, Lohnert AY, Maschmeyer G, Teschner D, Ullmann AJ, Penack O, Ruhnke M, Mayer K, Ostermann H, Wolf HH, Cornely OA (2018) Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol 97:197\u2013207. https:\/\/doi.org\/10.1007\/s00277-017-3196-2","journal-title":"Ann Hematol"},{"key":"6289_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","volume":"55","author":"B Moriyama","year":"2012","unstructured":"Moriyama B, Henning SA, Leung J, Falade-Nwulia O, Jarosinski P, Penzak SR, Walsh TJ (2012) Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 55:290\u2013297. https:\/\/doi.org\/10.1111\/j.1439-0507.2011.02158.x","journal-title":"Mycoses"},{"key":"6289_CR22","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1200\/JCO.2007.12.3851","volume":"25","author":"E Robenshtok","year":"2007","unstructured":"Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, Paul M (2007) Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 25:5471\u20135489. https:\/\/doi.org\/10.1200\/JCO.2007.12.3851","journal-title":"J Clin Oncol"},{"key":"6289_CR23","doi-asserted-by":"publisher","first-page":"e70074","DOI":"10.1111\/myc.70074","volume":"68","author":"D Seidel","year":"2025","unstructured":"Seidel D, Pana ZD, Ebrahimi-Fakhari D, Butzer SK, Mehler K, Reinhold I, Simon A, Dohna-Schwake C, Mack I, Bodmer N, Niehues T, Claviez A, Langler A, Leipold A, Prokop A, Brummel B, Winkler B, Gruhn B, Classen CF, Friedrich C, Koenig C, Flotho C, Poyer F, Schilling F, Calaminus G, Sieben G, Schwabe GC, Reinhard H, Teltschik HM, Hengartner H, Stursberg J, Greiner J, Greil J, Leyh J, Kuhl JS, Ehlert K, Bochennek K, Rohde M, Demmert M, Stiefel M, Eyrich M, Siepermann M, Fruhwald M, Doring M, Nathrath M, Minkov M, Streiter M, Jones N, Naumann-Bartsch N, Jorch N, Beck O, Beier R, Crazzolara R, Kietz S, Vieth S, Frohling S, Lobitz S, Ghosh S, Vallee TC, Muller T, Wiesel T, Dabritz T, Kontny U, Thiel U, Strenger V, Eberl WR, Cornely OA, Groll AH, Lehrnbecher T (2025) Approaches to invasive fungal diseases in paediatric cancer centres: an analysis of current practices and challenges in Germany. Austria Switz Mycoses 68:e70074. https:\/\/doi.org\/10.1111\/myc.70074","journal-title":"Austria Switz Mycoses"},{"key":"6289_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.25646\/11438","volume":"8","author":"C Spix","year":"2023","unstructured":"Spix C, Erdmann F, Grabow D, Ronckers C (2023) Childhood and adolescent cancer in Germany-an overview. J Health Monit 8:79\u201394. https:\/\/doi.org\/10.25646\/11438","journal-title":"J Health Monit"},{"key":"6289_CR25","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","volume":"78","author":"J Stemler","year":"2023","unstructured":"Stemler J, Mellinghoff SC, Khodamoradi Y, Sprute R, Classen AY, Zapke SE, Hoenigl M, Krause R, Schmidt-Hieber M, Heinz WJ, Klein M, Koehler P, Liss B, Koldehoff M, Buhl C, Penack O, Maschmeyer G, Schalk E, Lass-Florl C, Karthaus M, Ruhnke M, Cornely OA, Teschner D (2023) Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J Antimicrob Chemother 78:1813\u20131826. https:\/\/doi.org\/10.1093\/jac\/dkad143","journal-title":"J Antimicrob Chemother"},{"key":"6289_CR26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","volume":"76","author":"NR Stone","year":"2016","unstructured":"Stone NR, Bicanic T, Salim R, Hope W (2016) Liposomal amphotericin B (AmBisome((R))): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs 76:485\u2013500. https:\/\/doi.org\/10.1007\/s40265-016-0538-7","journal-title":"Drugs"},{"key":"6289_CR27","doi-asserted-by":"publisher","unstructured":"Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Kruger W, Mousset S, Neuburger S, Neumann S, Penack O, Silling G, Vehreschild JJ, Einsele H, Maschmeyer G, Infectious Diseases Working Party of the German Society for H, Medical O, The D-K (2016) Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol 95:1435\u20131455. https:\/\/doi.org\/10.1007\/s00277-016-2711-1","DOI":"10.1007\/s00277-016-2711-1"},{"key":"6289_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.medmal.2016.03.008","volume":"46","author":"G Venton","year":"2016","unstructured":"Venton G, Adam H, Colle J, Labiad Y, Mercier C, Ivanov V, Suchon P, Fanciullino R, Farnault L, Costello R (2016) Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia. Med Mal Infect 46:226\u2013229. https:\/\/doi.org\/10.1016\/j.medmal.2016.03.008","journal-title":"Med Mal Infect"},{"key":"6289_CR29","doi-asserted-by":"publisher","first-page":"e25448","DOI":"10.1097\/MD.0000000000025448","volume":"100","author":"E Yang","year":"2021","unstructured":"Yang E, Choi EJ, Park HS, Lee SO, Choi SH, Kim YS, Lee JH, Lee JH, Lee KH, Kim SH (2021) Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: a single-center, observational, case-control study in South Korea. Medicine (Baltimore) 100:e25448. https:\/\/doi.org\/10.1097\/MD.0000000000025448","journal-title":"Medicine (Baltimore)"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06289-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06289-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06289-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:35:31Z","timestamp":1757478931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06289-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["6289"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06289-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7086182\/v1","asserted-by":"object"}]},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were in accordance with the ethical standards. The study has been approved by the Jena University Hospital Ethics Committee (2024-3397). Informed consent was obtained from all individual participants or the responsible persons included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"235"}}